SCHEMBL6078652

SCHEMBL6078652

COC(C)C(CS(=O)(=O)Cc1cnc2ccccc2c1)NO

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP1A2 P05177 1/20 0.39
HIF1A Q16665 1/20 0.39
EPAS1 Q99814 1/20 0.39
FAAH O00519 8/20 0.39
PDE10A Q9Y233 4/20 0.38
MMP2 P08253 2/20 0.38
MMP9 P14780 2/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.37
MMP1 P03956 1/20 0.36
FCER2 P06734 1/20 0.36
MMP3 P08254 1/20 0.36
TRPM5 Q9NZQ8 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078647 1.00 KMT2A (0.40) KMT2AKDM4ESMN1; SMN2CYP1A2HIF1A
SCHEMBL6606289 0.89 CYP1A2 (0.42) KMT2AKDM4ESMN1; SMN2CYP1A2HIF1A
SCHEMBL6078177 0.89 KDM4E (0.40) KMT2AKDM4ESMN1; SMN2CYP1A2HIF1A
SCHEMBL6079552 0.89 KDM4E (0.40) KMT2AKDM4ESMN1; SMN2CYP1A2HIF1A
SCHEMBL6665570 0.86 KDM4E (0.40) KMT2AKDM4ESMN1; SMN2CYP1A2HIF1A
SCHEMBL6077699 0.85 CYP1A2 (0.37) KMT2AKDM4ESMN1; SMN2CYP1A2HIF1A
SCHEMBL6077240 0.84 HDAC4 (0.44) KMT2AKDM4ESMN1; SMN2FAAHPDE10A
SCHEMBL6987795 0.83 CYP1A2 (0.43) KMT2AKDM4ESMN1; SMN2CYP1A2HIF1A
Hydrochloric Acid SCHEMBL6078291 0.82 CYP1A2 (0.41) KMT2AKDM4ESMN1; SMN2CYP1A2HIF1A
SCHEMBL6608596 0.82 KMT2A (0.41) KMT2AKDM4ESMN1; SMN2CYP1A2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7038055-B2 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies SMITHKLINEBEECHAM PLC (GB) 2006-05-02 US disclosed
EP-1448529-B1 SULFONE DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND ALLERGIES SMITHKLINE BEECHAM PLC (GB) 2005-07-13 EP disclosed
US-20050070572-A1 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies SMITHKLINE BEECHAM PLC (GB) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070572-A1 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies CD2, SSB, CD22 KMT2A 3267/4885KDM4E 3353/4885SMN1; SMN2 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.